The novel mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ ERK5) pathway has been implicated in the regulation of cellular proliferation. MEK5 expression has been detected in prostate cancer cells, although the significance of the MEK5/ERK5 pathway in human prostate cancer has not been tested. We examined MEK5 expression in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and compared the results to clinical parameters. We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. Strong MEK5 expression correlates with the presence of bony metastases and less favourable disease-specific survival. Furthermore, among the patients with high Gleason score of 8-10, MEK5 overexpression has an additional prognostic value in survival. MEK5 transfection experiments confirm its ability to induce proliferation (Po0.0001), motility (P ¼ 0.0001) and invasion in prostate cancer cells (P ¼ 0.0001). MEK5 expression drastically increased MMP-9, but not MMP-2 mRNA expression. Luciferase report assays suggest that the À670/MMP-9 promoter is upregulated by MEK5 and electromobility shift assay further suggests the involvement of activator protein-I (AP-1), but not the NF-jB, binding site in the MMP-9 promoter. Using an AP-1 luciferase construct, activation of MEK5 was confirmed to enhance AP-1 activities up to twofold. Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis. As the MEK5/ERK5 interaction is highly specific, it represents a potential target of therapy.
Introduction
Adenocarcinoma of the prostate gland is the most common form of malignancy diagnosed among American men, accounting for over 35% of all male cancers (Greenlee et al., 2001) . Approximately 20% of these men will eventually die from their disease. Bone metastasis is associated with a significantly worse outcome and is a frequent late complication. The pathophysiology of bone metastases in prostate cancer is poorly understood, although in other tumour types accumulating evidence suggests that osteotropism may be related to an ability to activate osteoclasts and stimulate bone resorption (Kostenuik et al., 1992; Thomas et al., 1999) . In prostate cancer, factors associated with metastasis include bone morphogenetic protein-6 (BMP-6), transforming growth factor b1 (TGF-b1) (Eastham et al., 1995; Hamdy et al., 1997) , interleukin-6 (IL-6) and IL-6 receptor (Okamoto et al., 1997; Adler et al., 1999) . BMP-6 expression in primary prostate cancer is associated with skeletal metastases (Autzen et al., 1998) .
MAP kinase kinases (MEKs/MAPKKs) represent a family of protein kinases upstream of the MAP kinases, which play a pivotal role in cell proliferation and apoptosis. Mitogen/extracellular signal regulated kinase kinase-5 (MEK5) encodes a 444-amino-acid protein with an overall 40% homology to the other MEK proteins (English et al., 1995; Zhou et al., 1995) . It regulates skeletal and myocardium development through its interaction with extracellular signal-related kinase-5 (ERK5), which activates MEF2 by phosphorylation (Kato et al., 1997) . Using a modified RT-PCR approach to study gene products encoding kinases in a panel of human-derived xenograft lines, expression of MKK3, MKK4 and MEK5 was detected in prostate cancer (Robinson et al., 1996) . However, the clinical and biological significance of these kinases, including MEK5, remains unclear.
In this study, we defined the significance of MEK5 overexpression in prostate cancer, demonstrating its association with metastatic disease and poor survival. We further confirmed its role in regulating proliferation, migration, invasion and protease production.
Results
MEK5 overexpression in prostate cancer is associated with tumour metastases and unfavourable survival outcome A series of benign (n ¼ 20) and malignant (n ¼ 127) samples of prostate tissue underwent immunostaining for MEK5. Of the 127 tumours, 24 (19%) expressed MEK5 weakly, 56 (44%) moderately and 47 (37%) strongly. Cytoplasmic MEK5 immunoreactivity was observed in the malignant glandular epithelium. In the 20 benign prostatic hypertrophy (BPH) cases, the cytoplasm of glandular epithelial cells generally expressed MEK5 at a low level (Figure 1a) . A total of 34 tumours (27%) were graded Gleason score 7 or below (well to moderately differentiated tumours), while 93 tumours (73%) had Gleason scores 8 or above (poorly differentiated). A trend of strong MEK5 expression was noted in high-grade tumours, although not reaching statistical significance (P ¼ 0.05). In all, 60 patients (47%) had bony metastases. Of the cases with metastases, 47% (n ¼ 28) exhibited high MEK5 protein expression. Only 28% (n ¼ 19) of the cases without metastases exhibited high MEK5 expression (P ¼ 0.03) Figure 1 MEK5 overexpression in prostate cancer. (a) Expression of MEK5 and ERK5: (i) weak MEK5 expression in BPH specimen ( Â 200 magnification); (ii) weak MEK5 expression in Gleason Score 4 prostate cancer ( Â 400 magnification as are images iii-v); (iii) high MEK5 expression in Gleason Score 8 specimen; (iv) high MEK5 expression in Gleason Score 10 specimen; (v) weak ERK5 expression in BPH; (vi) increased ERK5 immunoreactivity in both cytoplasm and nuclei in Gleason Score 8 prostate cancer specimen ( Â 1000 magnification); (vii) high MEK5 expression in positive control heart specimen ( Â 400 magnification as is image viii); and (viii) absence of MEK5 expression in heart specimen without primary antibody (negative control). (b) MEK5 and metastases. MEK5 expression was grouped into weak/moderate (') and strong (&) . Expression was corroborated with the presence of metastases. A higher proportion of patients with strong MEK5 expression were seen in the group with metastases compared to those with no metastases (P ¼ 0.03). (c) Kaplain-Meier survival analysis plot of all cases. Patients with moderate/strong (++/+++) MEK5 expression had a shorter mean disease-specific survival of 52 months compared to those exhibiting weak MEK5 expression (+), 58 months. Log rank analysis revealed this difference to be significant (P ¼ 0.03 log rank test). (d) Kaplain-Meier survival analysis plot of cases with Gleason sum score of 8-10 only. Patients with a high Gleason sum score of 8-10 yet weak or negative (À/+) MEK5 protein expression had a longer mean cancer-specific survival of 64 months compared to those patients with moderate/ strong MEK5 protein expression whose mean cancer-specific survival was 54 months (P ¼ 0.03 log rank test). (e) MEK5 protein expression in prostatic tissue samples. Tissue samples were lysed and subjected to Western blotting as described in Materials and methods. Blots were probed with a monoclonal antibody to MEK5. Blots were reprobed with a-tubulin to verify loading. (Figure 1b) . The presence of metastases in prostate cancer is associated with poor survival. Here, we have confirmed that a high level of MEK5 expression was also significantly associated with less favourable disease survival (Figure 1c) . The mean disease-specific survival in the group with high MEK5 expression was 52 months and that of the group with low MEK5 expression, 58 months. Among patients with high-grade disease (Gleason score 8-10), high levels of MEK5 expression was a significant predictor of poor disease-specific survival (Figure 1d ). MEK5 protein expression in resected prostate specimens was also confirmed as a 50 kDa band in Western blotting. High-grade prostate cancers generally have higher levels of MEK5 expression than low-grade tumours and specimens from benign prostate hyperplasia (Figure 1e ).
ERK5 protein expression in prostate cancer (n ¼ 19) was also confirmed to be upregulated when compared to benign prostatic hyperplasia (n ¼ 10). In high-grade tumours, ERK5 immunoreactivity demonstrated both cytoplasmic and nuclear patterns, while in benign prostate tissue ERK5 signals were exclusively cytoplasmic, in keeping with activation of the MEK5/ERK5 pathway in prostate cancer.
MEK5 overexpression promotes cellular proliferation, motility and invasion
To investigate the roles of the MEK5/ERK5 signalling pathway in cell growth and function, we used an ecdysone-inducible system to express a constitutively activated mutant of MEK5 (MEK5D) Figure 2a (Abe et al., 1996) . FACS analysis of EcRD cells revealed a 56% increase of cells into the S phase of the cell cycle, peaking at 16 h ( Figure 2b ). As controls, both uninduced MEK5D-transfected cells and Ponasterone-induced control EcR293 cells showed no signs of an enhanced S phase (data not shown). To assess the level of proliferation resulting from the expression of MEK5D in human prostate cells, a WST-1 assay was performed using MEK5D-transfected LNCaP cells. The proliferative index of MEK5D-expressing cells was 3.7-fold greater than that of LNCaP cells transfected with the vector alone (Po0.0001) (Figure 2c) . Along with the FACS data, the WST-1 result further supports a role for the MEK5/ERK5 pathway in cellular proliferation.
Our IHC data indicates a correlation between strong MEK5 protein expression with the presence of metastatic disease. To examine this further, we evaluated the role of MEK5 in cellular migration and invasion. In MEK5D-expressing LNCaP cells, the migration index was found to be 1.8-fold (P ¼ 0.0001), and the invasion index 2.1-fold greater than in LNCaP cells transfected with vector alone (Po0.0001) (Figure 2d, e) . This migration and invasion data provide further evidence to suggest a role for MEK5/ERK5 in tumour invasion and metastasis.
MEK5 enhances MMP-9 expression
We identified a significant correlation between MEK5 overexpression and the presence of bony metastases in LNCaP-V and LNCaP-D cells were put onto cell culture inserts with 8 mm pores with RPMI medium with 10% foetal calf serum on both sides of the membrane. After 48 h, the cells were fixed, stained and counted in 10 separate fields on the membrane. Each assay was performed four times, normalized to the LNCaP-V line, and t-tests performed (P ¼ 0.0001). (e) Invasion assay. LNCaP-V and LNCaP-D cells were put onto the cell culture inserts coated with Matrigel suspended in 0.9 ml RPMI with 1% foetal calf serum. A volume of 0.9 ml of RPMI+10% foetal calf serum and 50 ng/ml of EGF was placed in the lower chambers. After 48 h, the cells were fixed, stained and counted in 10 separate fields on the membrane. Each assay was performed four times, normalized to the LNCaP-V line, and t-tests performed (Po0.0001) (Figure 3a) . We observed no influence of PonA-induced MMP transcription in the control cell line, EcR293 (data not shown). The MAPK members ERK and p38 have previously been demonstrated to stimulate MMP promoter activity. We next evaluated the contribution of the MEK5 pathway to MMP-2 and MMP-9 promoter activity. The MMP-9 promoter contains multiple activator protein-1 (AP-1) and NFkB binding sites. The À670 region of the MMP-9 promoter, upstream to the transcription initiation start site, contains two AP-1 and one NF-kB consensus binding sites, known to be required for effective MMP-9 transcriptional activation (Sato and Seiki, 1993) . Expression of MEK5D increased À670/MMP-9 promoter activity by approximately 1.5-fold (Figure 3b ). In contrast, MEK5D had no effect on the À73/MMP-9 construct, which contains no AP-1 or NF-kB cisacting elements. We observed no induction of the MMP-2 promoter by MEK5D. The responsive nature Total RNA was isolated from subconfluent PonA-induced/ uninduced EcRD or control (EcR293) cells and reverse transcribed. cDNA was subjected to PCR for MMP-2, MMP-9 and b-actin. A water template (c) and a minus MMLV-RT reaction were included as controls. Experiments were repeated in triplicate on two separate clones, EcRD No. 11 and No. 16, respectively. Densitometric analysis was performed to assess levels of induction. Expression of MEK5D results in induced MMP-9 expression. (b) MMP promoter activity. HEK293 cells were transfected with the MMP-2 (À1659) and MMP-9 (À670, À73) promoter-luc constructs and cotransfected with MEK5D or empty plasmid. Transfection efficiency was assessed and normalized to b-galactosidase activity. Data represents mean fold induction compared to basal level of promoter activity from sets of quadruplicate assays 7s.e. Experiments were performed three times. (c) MMP-9/AP-1 EMSA. EMSA was performed on the nuclear extracts (30 mg) from PonA-induced EcRD No. 16 or control (EcR293) cells using end-labelled oligonucleotide duplexes for AP-1 and NF-kB cis-elements spanning the MMP-9 promoter (À670). The parenthesis indicates a DNA duplex/AP-1-bound complex. Competition experiments were performed with 100-fold excess unlabelled (cold) probe. The control cell line, EcR293, was also subjected to AP-1 gel retards as described above. (d) AP-1 activity. HEK293 cells were cotransfected with an AP-1-luc construct and MEK5D or empty plasmid. Transfection efficiency was assessed and normalized to b-galactosidase activity. Data represent mean fold induction compared to basal level of promoter activity from sets of quadruplicate assays 7s.e. Experiments were performed in duplicate of all constructs examined was verified using serum as a positive control (data not shown).
The multiple cis-acting AP-1 and NF-kB elements on the MMP-9 promoter are required for effective MMP-9 transcriptional activation. Results from the MMP-9 promoters suggest that these sites may be involved in MEK5/ERK5-induced MMP-9 transcription. We performed an electromobility shift assay on PonA-induced and uninduced EcRD nuclear extracts incubated with an oligonucleotide duplex containing either an AP-1 or NFkB cis-element from the À670/MMP-9 region (Figure 3c ). Induction for MEK5D expression enhances the interaction between AP-1 protein to the consensus binding site within the À670 bp 5 0 -flanking region upstream of the transcription initiation start site of the MMP-9 promoter. This binding was shown to be specific and was competed out by the addition of a 100-fold molar excess of unlabelled probe. The experiment was also performed on nuclear extracts from the control cell line, EcR293, confirming the absence of interaction with AP-1 protein despite treatment with PonA ( Figure 3c ). We noted the presence of basal level of AP-1 bound protein complexes present in extracts from uninduced cells, observed in both EcRD and EcR293 cells. The À670/MMP-9 NF-kB cis-element did not retard any NF-kB protein complexes, suggesting that this particular element within the region of the MMP9 promoter is not involved in MEK5/ERK5-induced MMP-9 transcription. A further transfection study was performed to verify the effect of MEK5D expression on AP-1 function. In the presence of functional MEK5, AP-1 transactivation activities were increased up to twofold (Figure 3d ), which is consistent with the notion that AP-1 mediates the MEK5/ERK5-induced MMP expression.
Discussion
The function of ERK is known to regulate a wide range of physiological activities as well as processes that contribute to tumourigenesis, including cellular proliferation and apoptosis. Although there is increasing evidence to support an increase in ERK1/2 activity in prostate cancer (Price et al., 1999) , the clinical and biological significance of such ERK function remains poorly examined. Here, we report our original findings of MEK5 overexpression in resected prostate cancer and its association with tumour metastases and poor survival outcome. We also demonstrated the impact of the MEK5/ERK5 pathway on cellular proliferation, migration, invasion and induction of protease production. Furthermore, we observed that among high-grade tumours with Gleason sum score in excess of 7, MEK5 overexpression was able to define a subgroup with the worst prognosis. This is particularly important and may allow the development of intense treatment protocol for patients with high-grade disease according to their MEK5 expression status.
Bone metastasis is common in prostate cancer and has an adverse influence on outcome. The pathobiology of bone metastases remains poorly understood. Our findings show that MEK5 expression was not significantly associated with tumour grade (differentiation); however, it was interesting to observe its association with the presence of bony metastases and disease-specific survival. A number of cytokines have been suggested to be associated with bone metastasis in prostate cancer, including BMP-6 (Autzen et al., 1998), TGF-b1 (Eastham et al., 1995), IL-6 and IL-6 receptor (Okamoto et al., 1997; Adler et al., 1999) . The link between their clinical association with metastatic disease and the mechanism explaining their biological function remains to be defined.
MEK5 expression has been demonstrated in multiple tissues with high levels in the developing heart and skeletal muscles, in keeping with its physiological role in the development and maintenance of myocytes (English et al., 1995) . MEK5 specifically interacts with and activates ERK5, or Big MAP kinase 1/BMK1, which was identified as an 815-amino-acid protein in a yeast two-hybrid screen (Zhou et al., 1995) . Activation of ERK5 has been demonstrated in cells in response to oxidative stress, hyperosmolarity and by mitogenic compounds (Kamakura et al., 1999) . More recently, the MEK5/ERK5 pathway was shown to be potently activated by epidermal growth factor in a Ras-independent manner (Kato et al., 1998) . Compared to the other MAPK family members, the downstream events resulting from activation of the MEK5/ERK5 pathway remain relatively uncharacterized. We demonstrate here that expression of a constitutively active mutant of MEK5 (MEK5D) results in an increase in cell proliferation. In examining the effects of MEK5D, we found that MEK5D expression promotes cells into the S phase of the cell cycle. This supports previous data where use of a dominant-negative ERK5 blocked EGF-induced proliferation in HeLa cells, specifically preventing S-phase entry (Kato et al., 1998) . Furthermore, our data from WST-1 assay in the human prostate cancer LNCaP cells is also consistent with a role of MEK5 to enhance cellular proliferation. Together, these data suggest a potential role for the MEK5/ERK5 pathway in mediating mitogen-induced signals in prostate cancer.
Biochemically, the MEK5/ERK5 pathway is uniquely specific; MEK5 appears to function entirely through the activation of ERK5. Hence, overexpression of MEK5 will be expected to result in ERK5 activation. In breast cancer cells, phosphorylation of ERK5 was observed as a consequence of abnormal activation of members of the EGF receptor family (Esparis-Ogando et al., 2002) . Such overactivation of receptor tyrosine kinases will be very much similar to the introduction of a constitutively active form of MEK5. Hence, the use of constitutive active MEK5 served the function of testing whether abnormal activation of the MEK5/ERK5 pathway has a role in human prostate cancer. Our data on ERK5 immunostaining suggested that there is an upregulation of ERK5 protein expression in high-grade prostate cancer when compared to benign prostatic hyperplasia. In addition to the cytoplasmic signals, we observed significant ERK5 nuclear immunoreactivity (Figure 1a(vi) ), in keeping with active ERK5, which is stimulated specifically by MEK5.
The development of tumour progression involves certain essential cellular processes including the production of extracellular matrix (ECM) degrading proteases and compromised cell adhesion (McCawley and Matrisian, 2000) . MMPs play an important role in ECM remodelling, and a positive correlation between MMP expression and tumour progression has been demonstrated in both human and animal studies (Foda and Zucker, 2001 ). Expression of MMP-9 has been implicated in enhancing the metastatic potential of multiple tumours including breast, ovarian and prostate cancer (Sehgal et al., 1998; Stack et al., 1998; Scorilas et al., 2001) . Of the known MMPs studied in the prostate, MMP-9 overexpression correlates with metastatic disease. Levels of MMP-9 mRNA and mature protein have both been shown to be elevated in malignant prostatic tissue, particularly in tumours that exhibit an aggressive and metastatic phenotype (Stearns and Wang, 1993; Hamdy et al., 1994; Wood et al., 1997) . Furthermore, expression of pro-MMP-9 protein and mRNA is induced in metastatic PC-3 prostate cancer cells, when grown in human foetal bone implants in SCID mice (Dong et al., 2001) . We observed that activation of MEK5 results in the upregulation of MMP-9 transcription, demonstrating a moderate increase in promoter activity and confirming this induction at the mRNA level. The elements controlling the expression of MMP-9 have been well characterized and include AP-1, NF-kB, Ets and Sp1 sites, mainly within À670 bp region upstream to the transcription start site (Sato and Seiki, 1993) . In particular, both the AP-1 and NF-kB binding sites have been shown to be important regulatory elements of the MMP-9 promoter (Ricca et al., 2000; Troussard et al., 2000) . Serum-induced activation of ERK5 results in the transcriptional activation of c-jun by the MEF2C transcription factor (Kato et al., 1997) . A consequence of this is an increase in the levels of AP-1 protein. We demonstrate that expression of MEK5D results in increased AP-1 function in both electromobility shift assay (EMSA) and luciferase reported assay. The MEK5/ERK5 pathway is also sufficient to activate NF-kB (Pearson et al., 2001) . However, no involvement of the -670/MMP-9 NF-kB element was observed. These data provide evidence towards a MEK5/ERK5-induced AP-1-mediated upregulation of MMP-9 transcription. The MEK5/ERK5 pathway plays an important role in transmitting EGF-induced cellular proliferation (Kato et al., 1998) . In squamous cell carcinoma cells, EGFinduced MMP-9 production was attributed, in part, to the sustained activation of the ERK1/2 pathway (McCawley et al., 1999) . However, the involvement of the MEK5/ERK5 pathway to this stimulation was not examined, and so should not be excluded as a contributor of this process.
Recent work has shown that MAP kinase inhibitors may attenuate tumour growth. The MEK1/2 inhibitor, PD98059, has been shown to reduce the threshold for cytotoxic drug-mediated cell death by ara-C (Stadheim  et al., 2000) , cisplatin (Hayakawa et al., 1999) , doxorubicin (Stone and Chambers, 2000) and camptothecin (Hetman et al., 1999) . Another MEK1 inhibitor, PD184352, has been shown to block the growth of colonic carcinoma cells in mice (Sebolt-Leopold et al., 1999) . No specific chemical inhibitor of the MEK5/ ERK5 pathway exists yet, but if developed might be used to attenuate the metastatic process in prostate cancer.
In summary, we have provided original data to support an important role of MEK5 overexpression in human prostate cancer and identify key aspects of its molecular mechanism in prostate carcinogenesis. This represents the first data to relate clinical outcome to the expression of a member of the MAPK family. Our ongoing studies on the MEK5/ERK5 signalling cascade in prostate cancer will facilitate the development of novel therapy.
Materials and methods

Antibodies
The polyclonal anti-MEK5 (Stressgen, USA) was optimized for immunohistochemical analysis (Jenkins et al., 2001) . Other antibodies used include monoclonal anti-HA (Santa Cruz Biotechnology), monoclonal b-actin antibody (Sigma-Aldrich, UK); anti-MEK5 (Upstate Biotechnology) and anti-ERK5/ BMKl antibody (a gift from JD Lee, The Scripps Research Institute, USA).
Tissue samples and immunohistochemistry
Transurethral resection of the prostate for outflow obstruction was performed on 127 patients with prostate cancer and 20 patients with BPH. The patients with prostate cancer were aged 46-87 years (mean 73 years). T-stage data were available on 107 patients (84%); T1 n ¼ 36 patients, T2 n ¼ 30, T3 n ¼ 29 and T4 n ¼ 12. Sections from blocks made from the above operations were cut at 4 mm, deparaffinized and rehydrated through graded alcohols. Endogenous peroxidase activity was removed (30% H 2 O 2 /100% methanol) and antigen retrieval performed using trypsin at 371C for 10 min, then blocked using a 1 : 20 normal goat solution for MEK5 for 10 min. Sections were incubated with a rabbit polyclonal MEK5 antibody (1 : 1000) overnight at 41C. Biotinylated goat anti-rabbit serum (1 : 250) was used as the secondary antibody and then slides were incubated in 1% Avidin-Biotin Complex (Vector Labs). 3,3 0 -Diamino-benzidine (Sigma) was used for antibody detection, and slides were counterstained in haematoxylin. The level of MEK5 immunoreactivity was graded as negative, weak, moderate or strong by two independent histopathologists, and data were compared with clinical parameters including Gleason score, tumour stage (presence or absence of bony metastases) and disease-specific survival. Immunohistochemistry for ERK5 was performed on 19 patients with prostate cancer and 10 patients with BPH using a method similar to that mentioned above, but a goat polyclonal ERK5 (1 : 100) primary antibody (Santa Cruz Biotechnology) was used with appropriate blocking serum and secondary antibody.
Plasmid construction and generation of stable clones
A constitutively active mutant of MEK5 (MEK5D-HA) was PCR amplified and ligated into the TA cloning vector (Invitrogen). TA-MEK5D was then subcloned by restriction digest into the cloning vectors pcDNA3.1 and pIND-Sp1 (vector of the Ecdysone-inducible system (Invitrogen)) using KpnI and NotI, to generate pcMEK5D and pIND-MEK5D, respectively. Both pcMEK5D and pIND-MEK5D sequences were confirmed by sequencing from both directions.
Ecdysone-responsive stable clones were generated by transfecting pIND-MEK5D into commercially available EcR293 cells (containing the VgRXR plasmid (Invitrogen)) using Superfect reagent according to the manufacturer's recommendation (Qiagen, UK). After 48 h, the media was replaced containing 400 mg/ml G418 and 400 mg/ml Zeocin (Invitrogen). Selective media was replaced every 4 days until clones began to be selected for over a period of at least another 2 weeks. Individual clones were trypsinized and expanded in selective medium. To check their authenticity, each clone was induced/ uninduced with 5 mm PonA for 24 h before whole cell lysates were subjected to SDS-PAGE and Western blotting for the HA epitope of MEK5D.
WST1 proliferation assay
LNCaP cells were transfected with pcMEK5D (LNCaP-D), or the empty vector ÀpcDNA3.1. (LNCaP-V). A WST1 assay was performed on these cells according to the manufacturer's instructions (Roche, UK). A total of 10 000 cells per well of each type were used in a 96-well plate format. After 24 h, the WST1 reagent was added and incubated for a further 2 h before reading the plate. Each assay was conducted in sets of eight and the experiment was performed twice. The proliferative index is the fold induction of proliferation of MEK5D-transfected cells compared to vector-only-transfected cells.
Migration assay
In all, 50 000 LNCaP-D or LNCaP-V cells were added to the upper portion of a cell culture insert with 8 mm pore size (Becton Dickinson). The volume in the upper chamber was made up to 200 ml with full medium (10% FCS), with 400 ml of medium in the lower chamber, then assays were incubated at 371C for 48 h. The cells on the upper surface were removed with a cotton bud, then the remaining migrated cells were fixed in methanol at À201C for 1 h, stained with haematoxylin for 1 h at room temperature, then with Scott's Tap water (MgSO 4 Á 7H 2 O, 200 g/l+NaHCO 3 , 20 g/l) for 2 min. Using a graticule, migrated cells were counted at Â 200 magnification in 10 different fields on each filter. The experiment was performed three times.
Invasion assay
Invasion chambers were prepared by diluting Matrigel (Becton Dickinson) 1/45 (v/v) with PBS and adding 100 ml of this to 24-well size, 8 mm pore, cell culture inserts and left to set overnight at 371C. A total of 100 000 LNCaP-D or LNCaP-V cells were added to the upper chamber, suspended in 500 ml RPMI +1% FCS. As a chemoattractant to the cells, 500 ml of complete medium containing 50 ng/ml Epidermal Growth Factor (Sigma-Aldrich, UK) was added to the lower chamber. After 48 h, filters were fixed, stained and counted as detailed for the migration assays. Experiments were performed three times.
Western blotting
Cells were lysed directly on plates with 6 Â SDS sample buffer containing 10% b-mercaptoethanol. Samples were denatured and analysed by SDS-PAGE, followed by transfer to nitrocellulose. Antibodies were used at the following dilutions: anti-HA, 1 : 500; anti-ERK5, 1 : 1000; anti-MEK5, 1 : 1000; and anti-a tubulin, 1 : 2000. Horseradish peroxidase-conjugated secondary antibodies were applied at 1 : 500 dilution and detected using enhanced chemiluminescence detection kit (ECL, Amersham). To determine MEK5 protein levels from tissues, samples mentioned above were snap frozen in liquid nitrogen then stored at À861C. Samples were homogenized in 250 ml of protein lysis buffer (50 mm Tris (pH 7.5), 150 mm NaCl, 0.2 mm Na 3 VO 4 , 0.5% NP-40, 1 mm PMSF, 1 mm DTT) containing protease inhibitors (25 mg/ml leupeptin, 25 mg/ml aprotinin and 25 mg/ml pepstatin). A BCA protein assay (Pierce) was performed to determine the protein concentration. A measure of 80 mg of each protein was subjected to SDS-PAGE and Western blotting, as mentioned above. Blots were probed with anti-MEK5, then stripped and reprobed with anti-a-tubulin to determine loading.
FACS analysis
Subconfluent cells grown on six-well plates were harvested by trypsinization and washed in ice-cold PBS. Cells were resuspended in propidium iodide permeabilization buffer (1% Triton X-100, PBS) for 5 min at 41C. To remove RNA, cells were treated with 1 mg/ml RNase A for 20 min at 371C. Samples were analysed immediately on a bench top FACScan flow cytometer (Becton Dickinson), where cellular fluorescence was measured after argon laser excitation at 488 nm. Data were analysed using the Lysis II software package (Becton Dickinson).
MMP promoter studies
At 48 h prior to transfection, 3 Â 10 4 HEK293 cells were seeded per well in a 48-well plate. MMP-9 (À670, À73) and MMP-2 (À1659) constructs containing 5 0 -flanking fragments upstream to the transcription initiation start site linked to a luciferase reporter gene (MMP-luc) were cotransfected with pcMEK5D or empty plasmid (pcDNA3.1) using Superfect reagent, according to the manufacturer's recommendation. After 24 h, cells were serum starved and left for another 16-24 h before luciferase activities were determined. For all transfections, cells were cotransfected with a b-gal-CMV plasmid to allow normalization of transfections. A total of 300 ng of DNA was transfected, which contained 100 ng MMP-luc, 150 ng MEK5D, and 50 ng b-galactosidase reporter.
AP-1 activation study
HEK293 cells were transfected with pcMEK5D as above. They were cotransfected with an AP-1 construct linked to a luciferase reporter gene (Stratagene). Medium was changed after 24 h and luciferase activity measured after a further 24 h. A total of 250 ng of DNA was transfected, which contained 100 ng AP1-luc, 50 ng b-galactosidase reporter and either 0 or 25 ng of pcMEK5D.
MMP RT-PCR
Total RNA was isolated from cultured cells using the Promega SV Total RNA isolation kit according to the manufacturer's protocol (Promega). Reverse transcription and PCR was performed as described previously (Yan et al., 2001) 
EMSA
Preparation of nuclear extracts and EMSA on cultured cells were performed as described previously (Yan et al., 2001) . Oligonucleotide duplexes spanning the MMP-9 cis-element of interest were as follows: AP-1, CTGACCCCTGAGTCAG-CACTT; NF-kB, CAGTGGATTTCCCCAGCC (Yan et al., 2001) .
Abbreviations BMP-6, bone morphogenetic protein-6; ERK5, extracellular signal-regulated kinase-5; IL-6, interleukin-6; MEK5, mitogen/extracellular-signal-regulated kinase kinase-5; MMP, matrix metalloproteinases; PonA, Ponasterone A; TGF-b1, transforming growth factor-b-1; AP-1, activator protein-1.
